HCPCS Level II code J2329 represents the injectable biologic ublituximab-xiiy billed per 1 mg. As a drug-specific HCPCS code, J2329 is used on outpatient and facility claims to report the administered dose of this monoclonal antibody therapy. Accurate use of this code matters nationally because it affects medical and pharmacy benefit adjudication, provider reimbursement, and drug utilization tracking for high-cost biologics.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for ublituximab-xiiy, typical sites of service for administration, and the billing scenarios where a per-milligram HCPCS drug code is applied. The publication also summarizes common modifiers associated with drug administration claims, outlines expected documentation elements for unit-based drug reporting, and highlights benchmark considerations for payers and providers.

This national-focused brief provides operational guidance on claim reporting and coding context, clarifies what the code denotes on service lines, and identifies areas where policy updates or payer-specific coverage rules typically affect claim processing. Data not available in the input.